Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide DDI with Warfarin and Metformin in Healthy Subjects
NCT02022254Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2013
- Primary completion
- Aug 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoints: Area under the metformin plasma concentration-time curve, Area under the S-warfarin plasma concentration-time curve and 1 more. Started Dec 2013; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02022254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022254.